Possible Treatment Pathway Found for Hard to Treat T-Cell Subtype

Scientists sequencing genomes from 88 tumors diagnosed as anaplastic large cell lymphoma, anaplastic lymphoma kinase negative (ALCL ALK-) have uncovered mutations in two genes that could together be largely responsible for driving the poor prognosis of this disease subtype.

Among non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphomas represent only about 15 percent of all such diagnoses annually. Among the subtype of T-cell NHLs is anaplastic large cell lymphoma (ALCL). This subtype is further divided into whether the disease is anaplastic lymphoma kinase positive or negative. When positive, the prognosis with treatment is very good. When negative, the prognosis is not good.

This new study, reported in the journal Cancer Cell, might shed some light on why that is the case as well as offer some potential paths for treatment.

The international team of researchers, led by Dr. Giorgio Inghirami of Weill Cornell Medical College and Dr. Raul Rabadan of Columbia University College of Physicians and Surgeons, carried out the genome sequencing of 88 such tumors and determined that 38 percent of them featured the same pair of mutations in genes referred to as JAK1 and STAT3.

Using cell cultures as well as animal models, the team looked at what happened when they left those mutations alone, and when they inhibited them. By inhibiting them, or blocking their activity, they found substantially less tumor growth.

These genes are found on the same cellular signaling pathway. As a consequence, their potential activity in driving tumor growth is greater than if they were on different pathways.

"Since you have two defects, you are pushing the gas much more powerfully than when you push once," said Dr. Inghirami, employing a vehicle metaphor to make his point.

Yet despite this, they are also more vulnerable to effective treatments on account of this as well. According to the researchers, there are drugs available that can inhibit the activity of JAK1, and if you can do that you can also inhibit STAT3 because its activity is contingent on the activity above it, in JAK1.

Since mutations in JAK1 and the harm they can cause are not new to science or medicine, some JAK1 inhibitors already exist for various disorders, and therefore represent possible markers for future treatment of persons diagnosed with ALCL ALK negative.

Source: Cancer Cell

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap